XOMA Announces Natasha Hernday Joins its Board of Directors
01 Luglio 2020 - 1:30PM
XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday,
Senior Vice President, Corporate Development at Seattle Genetics,
Inc., has joined the Company’s Board of Directors. Ms.
Hernday has 20 years of experience in corporate development and
corporate strategy work and an extensive record of asset licensing,
partnerships, and acquisition transactions.
“We graciously welcome Natasha to the XOMA Board of
Directors. Natasha has had an exceptional career in corporate
development, both at Seattle Genetics and at Amgen. Her
expertise in sourcing, evaluating and negotiating licensing deals,
acquisitions, and partnerships are complementary to our royalty
aggregator business model and are expected to benefit XOMA and our
stakeholders as we continue to build our royalty portfolio,” said
Jim Neal, Chief Executive Officer at XOMA.
“XOMA’s royalty aggregator business model focuses heavily on
business development activities within the biotech industry to
benefit patients and shareholders. These align with my
personal passions and professional expertise. I look forward
to joining the XOMA Board to help the Company further its mission
of advancing breakthroughs in human health through its royalty
aggregation strategy,” commented Ms. Hernday.
Ms. Hernday joined Seattle Genetics in 2011 and is responsible
for the Company’s in-licensing, collaboration and acquisition
transactions, in addition to serving as a member of the Executive
Committee. Notably, her team led the 2018 acquisition of
Cascadian Therapeutics, which included TUKYSA™ (tucatinib), which
received marketing approval in the U.S. and Switzerland in
2020. Prior to joining Seattle Genetics, she spent 16 years
at Amgen, initially in research, then transitioning into project
management and ultimately corporate development. Ms. Hernday
has served on the Board at PDL BioPharma, Inc., since June
2019. Ms. Hernday received her Masters in Business and
Administration from Pepperdine University and her Bachelors degree
in Microbiology with an emphasis on Medical Microbiology from
University of California Santa Barbara.
About XOMA CorporationXOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotechnology and pharmaceutical
companies. The Company’s portfolio of partner-funded programs
spans multiple stages of the drug development process and across
various therapeutic areas. Many of these licenses are the
result of XOMA’s pioneering efforts in the discovery and
development of antibody therapeutics. The Company’s
royalty-aggregator business model includes acquiring additional
licenses to programs with third-party funding. For more
information, visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
creating additional value for the stockholders, cash sufficiency
forecast, economic outlook, and potential impact of the COVID-19
pandemic. These statements are based on assumptions that may
not prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry, including those related to the fact that
our product candidates subject to out-license agreements are still
being developed, and our licensees may require substantial funds to
continue development which may not be available; we do not know
whether there will be, or will continue to be, a viable market for
the products in which we have an ownership or royalty interest; if
the therapeutic product candidates to which we have a royalty
interest do not receive regulatory approval, our third-party
licensees will not be able to market them, and the impact to the
global economy as a result of the COVID-19 pandemic. Other
potential risks to XOMA meeting these expectations are described in
more detail in XOMA's most recent filing on Form 10-K and in other
SEC filings. Consider such risks carefully when considering
XOMA's prospects. Any forward-looking statement in this press
release represents XOMA's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. XOMA disclaims any obligation to
update any forward- looking statement, except as required by
applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development.
Investor contact: Juliane Snowden Oratorium
Group, LLC +1 646-438-9754 jsnowden@oratoriumgroup.com
Media contact: Kathy Vincent KV Consulting
& Management +1 310-403-8951 kathy@kathyvincent.com
Grafico Azioni XOMA (NASDAQ:XOMA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni XOMA (NASDAQ:XOMA)
Storico
Da Apr 2023 a Apr 2024